Performance of the CARDIOGARD Cannula

Coronary Artery Disease Clinical Trial

— GECG  

Official title:

A Study to Collect Additional Information Related to the Performance of the CARDIOGARD Cannula

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02764645
• Other study ID #: CLNG100 Full Protocol
• Status: Not yet recruiting
• Phase: N/A
• First received: March 22, 2016
• Last updated: May 5, 2016
• Start date: May 2016
• Est. completion date: May 2019

Study information

• Verified date: May 2016
• Source: Rambam Health Care Campus
• Contact: Roi - Glam, MD
• Phone: +972-4-7772631
• Email: r_glam[@]rambam.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

This is a single center, prospective study:

The 'CardioGard Cannula' Gaseous emboli capture results - shows an improvement from the control group.

Description:

Patients referred for CPB procedure will be offered to participate in the study. Patients will be asked to sign an informed consent form (ICF), prior to performing any study related procedures.

The point of enrollment is the time at which a patient signs and dates the ICF. Following enrollment, the patient will undergo screening evaluation (including Neurological assessment) to determine eligibility. Screening failures will be identified on a screening log. Patients who are found to meet all inclusion criteria and none of the exclusion criteria will compose the evaluable cohort of the study. Screening failure subjects will not be counted as part of the target patient sample size nor will they be included in the analysis.

Patients in the randomized phase will have surgery with the CardioGard Cannula or comparator cannulae and will remain blinded to their group assignment through the 30 days follow-up evaluation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 400
• Est. completion date: May 2019
• Est. primary completion date: May 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 50 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Patient indicated for first-time non-emergent procedure under cardiopulmonary bypass which is expected to last up to 6 hours.

2. Patient undergoing an elective isolated coronary artery bypass surgery (CABG), or an elective isolated aortic/mitral valve replacement (AVR/MVR) or an elective combined aortic/mitral valve replacement (AVR/MVR) with coronary artery bypass surgery (CABG).

3. The patient is >50 and <85 years of age.

4. The patient's body weight is compatible with blood net flow of 4 - 5 [l/min].

5. Patient with left ventricular ejection fraction >30% as assessed by either echocardiography, angiography or by radio nuclear assessment (MUGA)

6. The patient is willing to participate as evidenced by signing the written informed consent.

7. Male or non-pregnant female patient (Note: Females of child bearing potential must have a negative pregnancy test)

Exclusion Criteria:

1. Patient with abnormal clotting mechanism: PT 60%, PTT>2 the normal.

2. Patient with an aortic trauma.

3. Patient contraindicated for open heart surgery under bypass machine.

4. Patient undergoing a re-do procedure.

5. Patient intended for an operation performed using minimally invasive surgical techniques (e.g., mini-sternotomy)

6. Patient with pathologies which affect his/her neurological condition.

7. Patient in whom emergency operation is required.

8. Patient with a known allergy to Heparin

9. Patient with major co-morbid condition(s) that could limit the patient's ability to participate in the study, or impact the scientific integrity of the study, including but not limited to:

• previous stroke

• critical preoperative state

• poor ventricular function

• severe pulmonary hypertension [19]

• Atheroembolism

• history of cardiac failure [20]

10. Current use of drugs that might result in high surgical risk or significant postoperative complication.

11. Psychological instability, inappropriate attitude or motivation.

12. Patients with life threatening debilitating disease other than cardiac.

13. Subjects currently enrolled in another investigational device or drug trial that has not completed the primary end point or that clinically interferes with the current study endpoints.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Heart Valve Diseases
• Myocardial Ischemia

Intervention

Device:
• CardioGard Cannula
CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure. The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration.
• 22Fr curved Cannula
arterial cannula for use in cardiac surgery

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Rambam Health Care Campus	CardioGard Medical Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The 'CardioGard Cannula' Gaseous emboli capturing ability	The gaseous emboli capturing ability of the cardiogard cannula will be evaluated using a bubbles counter. .	36 months	No
Secondary	The amount of emboli particles which evacuated from the cardiopulmonarybypass machine by the CardioGard Cannula	Using the suction feature, External filters will be analyzed in order to recover particulate matter.	36 months	No
Secondary	The Neurological effect of reducing gaseous emboli from the heart during cardiac surgery.	The ability of the Cardiogard cannula will be evaluated using Neurological questionnaires.	36 months	No